PexacerfontAlternative Names: BMS-562086
Latest Information Update: 04 Jun 2010
At a glance
- Originator Bristol-Myers Squibb
- Class Antidepressants; Anxiolytics; Pyrazoles; Small molecules
- Mechanism of Action Corticotropin-releasing factor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Generalised anxiety disorder; Irritable bowel syndrome; Major depressive disorder